About the Startup
Dresden-based healthtech startup developing MyeloAID, an AI-powered bone marrow diagnostic software that analyzes bone marrow samples faster and more precisely, platform-independent and compatible with existing microscopes and scanners. Focused on blood cancer diagnostics and digital biomarkers to improve precision medicine for hematology patients.
Source: https://tech.eu/2026/01/20/dresden-spin-off-cancilico-closes-eur25m-round-to-advance-ai-in-oncology/
Frequently Asked Questions
What type of funding round did Cancilico raise?
Cancilico raised a seed round.
How much did Cancilico raise in its seed?
Cancilico raised $2,500,000 USD in its seed.
When did Cancilico raise its seed?
Cancilico raised its seed on 2026-01-20.
Who invested in Cancilico's seed?
The investors in Cancilico's seed are: High-Tech Gründerfonds (HTGF), TGFS - Technologiegründerfonds Sachsen, GEDAD GmbH, ROI Verwaltungsgesellschaft (Roland Oetker).
What type of investment was Cancilico's seed?
Cancilico's seed was a equity investment.